Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alseres Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (553)	3/20/1998 8:44:00 PM
From: dipper	Respond to of 975

I have invested rather heavily in this company since 10/97. My reasons are that I have never seen a biotech trading at $2-3 with so many near term prospects (Altropane, etc.) Couple this with a low burn rate of cash (being a so-called "virtual" company). My interest lies in the fact that the market still relates this company 100% to the failures of Therafectin to gain approval. I have discounted T-fectin completely in my investment decision, but naturally would welcome the amended approval. I told Dr. Lanser that his problems are with EXPOSURE. Wall Street needs to be educated, and there are plenty of people out there that never heard of the Greenwhich Pharm woes and, therefore, the 100% association of this company to T-fectin. With 12 plus million shares outstanding, it doesn't take much exposure and education to some new investors on the STREET to bolster the performance of the stock (presently a $25 million market cap). I welcome your comments. Also, have you seen the Synapse Journal articles on Altropane yet? I am still searching.

To: Dr. John M. de Castro who wrote (553)	4/3/1998 12:38:00 PM
From: dipper	Read Replies (1) \| Respond to of 975

heard that Synapse medical journal vol 29/issue 2 has been sent out to circulation. Very positive 4 pages on Altropane. First major pub. on this R & D. Am going to see if I can get into medical library or get reprints. Will update.